Generative AI platform for mRNA therapeutics
Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, announced the publication of data from its generative AI platform in Science. The data supports Raina's pioneering approach to mRNA design using its GEMORNA platform to generate novel sequences with superior drug properties over existing mRNA discovery methods.
Founded by a team with deep RNA therapeutics and AI expertise, the Company’s mission is to transform the mRNA-based therapeutics landscape by accelerating drug discovery timelines and opening new therapeutic areas for mRNA with best-in-class AI-designed therapeutics.
The Science article marks a significant landmark for optimizing novel mRNAs with enhanced expression and durability to facilitate a wide range of therapeutic mRNA applications.
The article, which was published by the journal Science, is summarized as follows:
· Raina’s GEMORNA platform designs superior linear and circular mRNA drug molecules with optimized expression levels and durability, addressing two major issues that have limited the effectiveness of mRNA-based therapeutics.
· GEMORNA is highly differentiated from prior RNA language models developed for predictive tasks through its direct design of novel sequences from a near infinite design space.
· GEMORNA-generated mRNAs:
o Elicited significantly higher immune response in mice compared to a leading commercially available mRNA vaccine sequence, potentially supporting mRNA therapeutic vaccine applications for diseases such as cancer.
o Achieved up to a 150-fold increase in human erythropoietin (hEPO) expression compared to an optimized benchmark, potentially supporting mRNA medicines for gene therapy.
o Demonstrated a 5-fold increase in CD19 CAR expression and a 2-fold improvement in durability compared to a patented benchmark, resulting in nearly 100% anti-tumor efficacy in primary human T cells, potentially supporting mRNA therapies for in vivo CAR-T.
